Elevance Health Files 8-K
Ticker: ELV · Form: 8-K · Filed: May 30, 2024 · CIK: 1156039
Sentiment: neutral
Topics: 8-k, reporting
TL;DR
ELEVANCE HEALTH FILES 8-K - STANDARD REPORTING UPDATE
AI Summary
Elevance Health, Inc. filed an 8-K on May 30, 2024, reporting an event that occurred on May 20, 2024. The filing pertains to "Other Events" and "Financial Statements and Exhibits." No specific financial transactions or material events are detailed in the provided text, beyond the standard reporting of these categories.
Why It Matters
This filing indicates Elevance Health is providing updates or disclosures related to its operations and financial reporting, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any immediate negative or positive material events.
Key Numbers
- 001-16751 — SEC File Number (Identifier for Elevance Health's filings)
- 35-2145715 — IRS Employer Identification No. (Tax identification for Elevance Health)
Key Players & Entities
- Elevance Health, Inc. (company) — Registrant
- Indiana (location) — State of incorporation
- Indianapolis (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by Elevance Health?
The provided text does not specify the details of the 'Other Events' beyond listing the category.
What 'Financial Statements and Exhibits' are included in this 8-K filing?
The provided text only lists 'Financial Statements and Exhibits' as an item information category and does not detail the specific contents.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 20, 2024.
What is the principal executive office address for Elevance Health?
The principal executive office address for Elevance Health is 220 Virginia Avenue, Indianapolis, IN 46204.
What is the telephone number provided for Elevance Health?
The telephone number provided for Elevance Health is (833) 401-1577.
Filing Stats: 1,562 words · 6 min read · ~5 pages · Grade level 10.2 · Accepted 2024-05-30 16:45:02
Key Financial Figures
- $600 million — nc.) (the "Company") closed its sale of $600 million aggregate principal amount of its 5.150
- $1,000 million — 150% Notes due 2029 (the "2029 Notes"), $1,000 million aggregate principal amount of its 5.375
- $2,572.4 million — pany received proceeds of approximately $2,572.4 million from the sale of the Notes after deduct
Filing Documents
- d819869d8k.htm (8-K) — 34KB
- d819869dex11.htm (EX-1.1) — 177KB
- d819869dex42.htm (EX-4.2) — 46KB
- d819869dex43.htm (EX-4.3) — 46KB
- d819869dex44.htm (EX-4.4) — 48KB
- d819869dex51.htm (EX-5.1) — 13KB
- d819869dex52.htm (EX-5.2) — 13KB
- g819869g0529212138180.jpg (GRAPHIC) — 2KB
- g819869new_capture.jpg (GRAPHIC) — 14KB
- 0001193125-24-150440.txt ( ) — 607KB
- elv-20240520.xsd (EX-101.SCH) — 3KB
- elv-20240520_lab.xml (EX-101.LAB) — 17KB
- elv-20240520_pre.xml (EX-101.PRE) — 11KB
- d819869d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Exhibit 1.1 Underwriting Agreement, dated as of May 20, 2024, among the Company and BofA Securities, Inc., Deutsche Bank Securities Inc. and U.S. Bancorp Investments, Inc. 4.1 Indenture, dated as of November 21, 2017, among the Company and the Bank of New York Mellon Trust Company, N.A. as trustee (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on November 21, 2017) 4.2 Form of the 5.150% Notes due 2029 4.3 Form of the 5.375% Notes due 2034 4.4 Form of the 5.650% Notes due 2054 5.1 Opinion of Hogan Lovells US LLP 5.2 Opinion of Faegre Drinker Biddle & Reath LLP 23.1 Consent of Hogan Lovells US LLP (included in the opinion filed as Exhibit 5.1) 23.2 Consent of Faegre Drinker Biddle & Reath LLP (included in the opinion filed as Exhibit 5.2) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 30, 2024 ELEVANCE HEALTH, INC. By: /s/ Kathleen S. Kiefer Name: Kathleen S. Kiefer Title: Chief Governance Officer & Corporate Secretary